FDA Clears First Device to Enable Automated Insulin Dosing for Individuals with Type 2 Diabetes

Estimated reading time: 1 minutes

• About The Author

FDA expands indications of the Insulet SmartAdjust technology, an interoperable automated glycemic controller previously indicated for the management of type 1 diabetes in individuals two years and older, to also include management of type 2 diabetes in individuals 18 years and older.

About The Author

See author's posts

Trending

Google Ranking Factors and Marketing KPIs